European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E. Canfield; Saeed Dabestani; Rachel H. Giles; Fabian Hofmann; Milan Hora; Markus A. Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S. Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2016.06.009

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Thomas Powles
, Michael Staehler
, Börje Ljungberg
, Karim Bensalah
, Steven E. Canfield
, Saeed Dabestani
, Rachel H. Giles
, Fabian Hofmann
, Milan Hora
, Markus A. Kuczyk
, Thomas Lam
, Lorenzo Marconi
, Axel S. Merseburger
, Alessandro Volpe
, Axel Bex

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

Lingua originale	Inglese
pagine (da-a)	705-706
Numero di pagine	2
Rivista	European Urology
Volume	70
Numero di pubblicazione	5
DOI	https://doi.org/10.1016/j.eururo.2016.06.009
Stato di pubblicazione	Pubblicato - 2016
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.eururo.2016.06.009

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Powles, T., Staehler, M., Ljungberg, B., Bensalah, K., Canfield, S. E., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., Volpe, A., & Bex, A. (2016). European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy. European Urology, 70(5), 705-706. https://doi.org/10.1016/j.eururo.2016.06.009

@article{6a00d342aafd4e969c00f8536a874bae,

title = "European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy",

abstract = "The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.",

keywords = "Cabozantinib, European Association of Urology, Guidelines, Nivolumab, Renal cancer",

author = "Thomas Powles and Michael Staehler and B{\"o}rje Ljungberg and Karim Bensalah and Canfield, \{Steven E.\} and Saeed Dabestani and Giles, \{Rachel H.\} and Fabian Hofmann and Milan Hora and Kuczyk, \{Markus A.\} and Thomas Lam and Lorenzo Marconi and Merseburger, \{Axel S.\} and Alessandro Volpe and Axel Bex",

note = "Publisher Copyright: {\textcopyright} 2016 European Association of Urology",

year = "2016",

doi = "10.1016/j.eururo.2016.06.009",

language = "English",

volume = "70",

pages = "705--706",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "5",

}

Powles, T, Staehler, M, Ljungberg, B, Bensalah, K, Canfield, SE, Dabestani, S, Giles, RH, Hofmann, F, Hora, M, Kuczyk, MA, Lam, T, Marconi, L, Merseburger, AS, Volpe, A & Bex, A 2016, 'European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy', European Urology, vol. 70, n. 5, pagg. 705-706. https://doi.org/10.1016/j.eururo.2016.06.009

TY - JOUR

T1 - European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

AU - Powles, Thomas

AU - Staehler, Michael

AU - Ljungberg, Börje

AU - Bensalah, Karim

AU - Canfield, Steven E.

AU - Dabestani, Saeed

AU - Giles, Rachel H.

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Lam, Thomas

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Volpe, Alessandro

AU - Bex, Axel

PY - 2016

Y1 - 2016

N2 - The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

AB - The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

KW - Cabozantinib

KW - European Association of Urology

KW - Guidelines

KW - Nivolumab

KW - Renal cancer

UR - https://www.scopus.com/pages/publications/84977627563

U2 - 10.1016/j.eururo.2016.06.009

DO - 10.1016/j.eururo.2016.06.009

M3 - Article

SN - 0302-2838

VL - 70

SP - 705

EP - 706

JO - European Urology

JF - European Urology

IS - 5

ER -

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo